DDX10 promotes the proliferation and metastasis of colorectal cancer cells via splicing RPL35

Abstract

Background Colorectal cancer (CRC) has become the second deadliest cancer in the world and severely threatens human health. An increasing number of studies have focused on the role of the RNA helicase DEAD-box (DDX) family in CRC. However, the mechanism of DDX10 in CRC has not been elucidated. Methods In our study, we analysed the expression data of CRC samples from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Subsequently, we performed cytological experiments and animal experiments to explore the role of DDX10 in CRC cells. Furthermore, we performed Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and protein–protein interaction (PPI) network analyses. Finally, we predicted the interacting protein of DDX10 by LC–MS/MS and verified it by coimmunoprecipitation (Co-IP) and qPCR. Results In the present study, we identified that DDX10 mRNA was extremely highly expressed in CRC tissues compared with normal colon tissues in the TCGA and GEO databases. The protein expression of DDX10 was measured by immunochemistry (IHC) in 17 CRC patients. The biological roles of DDX10 were explored via cell and molecular biology experiments in vitro and in vivo and cell cycle assays. We found that DDX10 knockdown markedly reduced CRC cell proliferation, migration and invasion. Then, we constructed a PPI network with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). GO and KEGG enrichment analysis and gene set enrichment analysis (GSEA) showed that DDX10 was closely related to RNA splicing and E2F targets. Using LC–MS/MS and Co-IP assays, we discovered that RPL35 is the interacting protein of DDX10. In addition, we hypothesize that RPL35 is related to the E2F pathway and the immune response in CRC. Conclusions In conclusion, provides a better understanding of the molecular mechanisms of DDX10 in CRC and provides a potential biomarker for the diagnosis and treatment of CRC.

Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation

“…Importantly, using data mining and qRT-PCR, we determined three genes involved in the CR-score signature, including DDX10, RBM34, and RPL17, that were higher expressed in BLCA than in normal tissues. Previous studies proved that DDX10 could promote proliferation or metastasis of tumor cells in lung cancer ( Liu et al, 2021 ), colorectal cancer ( Zhou et al, 2022 ), and ovarian cancer ( Gai et al, 2016 ). However, its role in bladder cancer has not been reported yet.…”

Potential mechanisms for predicting comorbidity between multiple myeloma and femoral head necrosis based on multiple bioinformatics

“…And it was found that RPS19 is overexpressed in bone marrow mesenchymal stem cells, and mutations in this gene cause Diamond-Blackfan anemia [18] . There are reports that RPS19 is signi cantly overexpressed in colorectal cancer tissues and cells, and a decrease in RPS19 expression can inhibit colorectal cancer cell growth and reduce tumorigenicity in nude mice [19] . Other studies have found that targeted up regulation of RPL15 expression in pancreatic cancer can inhibit the growth of pancreatic cancer cells [20] .…”

DDX52 gene expression in LUAD tissues indicates potential as a prognostic biomarker and therapeutic target

“…Altered expression and activity of these genes are observed across various malignancies, impacting cancer cell behaviors such as proliferation and migration. For instance, DDX10’s high expression in colorectal cancer tissues suggests its potential as a diagnostic and therapeutic marker 24 . Similarly, suppressing the overexpressed DDX56 inhibits gastric cancer growth, indicating its therapeutic potential 25 .…”